{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:45:05Z","timestamp":1769885105241,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ando.2025.101700","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:23:41Z","timestamp":1736871821000},"page":"101700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chapter 11: Treatment modalities"],"prefix":"10.1016","volume":"86","author":[{"given":"Gr\u00e9gory","family":"Baud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Espiard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Ben Hamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9loise","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunza Cinzia","family":"Paladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101700_bib0435","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","article-title":"Hyperparathyroidim","volume":"391","author":"Bilezikian","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2025.101700_bib0440","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0445","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/jbmr.4689","article-title":"Surgical aspects of primary hyperparathyroidism","volume":"37","author":"Perrier","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0450","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/jc.2012-3168","article-title":"Clinical review: parathyroid localization and implications for clinical management","volume":"98","author":"Kunstman","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0455","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0460","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1210\/jc.2014-2000","article-title":"The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Udelsman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0465","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/SLA.0b013e318208fed9","article-title":"The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism","volume":"253","author":"Udelsman","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0470","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.surg.2013.04.020","article-title":"Factors in conversion from minimally invasive parathyroidectomy to bilateral parathyroid exploration for primary hyperparathyroidism","volume":"154","author":"Hughes","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0475","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/SLA.0000000000000812","article-title":"Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years","volume":"261","author":"Abdulla","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0480","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00268-007-9068-5","article-title":"1112 consecutive bilateral neck explorations for primary hyperparathyroidism","volume":"31","author":"Allendorf","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0485","doi-asserted-by":"crossref","first-page":"352","DOI":"10.21037\/gs.2016.01.06","article-title":"Endoscopic and robotic parathyroidectomy in patients with primary hyperparathyroidism","volume":"5","author":"Brunaud","year":"2016","journal-title":"Gland Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0490","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/SLA.0000000000000207","article-title":"Predictors of recurrence in primary hyperparathyroidism: an analysis of 1386 cases","volume":"259","author":"Schneider","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0495","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archsurg.138.10.1140","article-title":"Incision length for standard thyroidectomy and parathyroidectomy: when is it minimally invasive?","volume":"138","author":"Brunaud","year":"2003","journal-title":"Arch Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0500","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00268-004-7638-3","article-title":"Results of video-assisted parathyroidectomy: single institution's six-year experience","volume":"28","author":"Miccoli","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0505","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/bjs.1800830656","article-title":"Endoscopic subtotal parathyroidectomy in patients with primary hyperparathyroidism","volume":"83","author":"Gagner","year":"1996","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0510","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s004230050207","article-title":"Minimally invasive videoscopic parathyroidectomy by lateral approach","volume":"384","author":"Henry","year":"1999","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0515","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1096-9098(199811)69:3<178::AID-JSO11>3.0.CO;2-9","article-title":"Video-assisted neck surgery: endoscopic resection of benign thyroid tumor aiming at scarless surgery on the neck","volume":"69","author":"Shimizu","year":"1998","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ando.2025.101700_bib0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00129689-200608000-00006","article-title":"Gasless endoscopic thyroidectomy via an axillary approach: experience of 30 cases","volume":"16","author":"Yoon","year":"2006","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"key":"10.1016\/j.ando.2025.101700_bib0525","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jviscsurg.2023.04.014","article-title":"Transoral endoscopic thyroidectomy vestibular approach (TOETVA). Recommendations of the AFCE (Francophone Association of Endocrine Surgery) with the SFE (French Society of Endocrinology) and the SFMN (French Society of Nuclear Medicine)","volume":"160","author":"Chereau","year":"2023","journal-title":"J Visc Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0530","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.surg.2011.09.041","article-title":"Case series of targeted parathyroidectomy with surgeon-performed ultrasonography as the only preoperative imaging study","volume":"150","author":"Deutmeyer","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0535","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.surg.2003.06.001","article-title":"Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate?","volume":"134","author":"Carneiro","year":"2003","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0540","first-page":"1019","article-title":"Clinical usefulness of an intraoperative \u201cquick parathyroid hormone\u201d assay","volume":"114","author":"Irvin","year":"1993","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0545","doi-asserted-by":"crossref","first-page":"106042","DOI":"10.1016\/j.ijsu.2021.106042","article-title":"The role of Rapid Intraoperative Parathyroid Hormone (ioPTH) assay in determining outcome of parathyroidectomy in primary hyperparathyroidism: a systematic review and meta-analysis","volume":"92","author":"Medas","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0550","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/jbmr.4689","article-title":"Surgical aspects of primary hyperparathyroidism","volume":"37","author":"Perrier","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0555","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1210\/jc.2011-3030","article-title":"Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor","volume":"97","author":"Yavuz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0560","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archsurg.140.2.146","article-title":"Applicability of tissue aspirate for quick parathyroid hormone assay to confirm parathyroid tissue identity during parathyroidectomy for primary hyperparathyroidism","volume":"140","author":"Lo","year":"2005","journal-title":"Arch Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0565","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1002\/hed.27538","article-title":"The utility of parathyroid autofluorescence as an adjunct in thyroid and parathyroid surgery 2023","volume":"45","author":"Pace-Asciak","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.ando.2025.101700_bib0570","doi-asserted-by":"crossref","first-page":"zraa047","DOI":"10.1093\/bjsopen\/zraa047","article-title":"Autofluorescence pattern of parathyroid adenomas","volume":"5","author":"Demarchi","year":"2021","journal-title":"BJS Open"},{"key":"10.1016\/j.ando.2025.101700_bib0575","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/lary.29880","article-title":"Parathyroid gland autofluorescence characteristics in patients with primary hyperparathyroidism","volume":"132","author":"Law","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ando.2025.101700_bib0580","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.surg.2018.08.006","article-title":"Heterogeneous and low-intensity parathyroid autofluorescence: patterns suggesting hyperfunction at parathyroid exploration","volume":"165","author":"Kose","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0585","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.soc.2022.08.004","article-title":"Advances in endocrine surgery","volume":"32","author":"Lui","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ando.2025.101700_bib0590","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12565-012-0142-1","article-title":"Location, number and morphology of parathyroid glands: results from a large anatomical series","volume":"87","author":"Lappas","year":"2012","journal-title":"Anat Sci Int"},{"key":"10.1016\/j.ando.2025.101700_bib0595","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/hed.26960","volume":"44","author":"Orloff","year":"2022","journal-title":"Head Neck"},{"key":"10.1016\/j.ando.2025.101700_bib0600","doi-asserted-by":"crossref","first-page":"e230067","DOI":"10.1530\/ETJ-23-0067","article-title":"2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management","volume":"12","author":"Durante","year":"2023","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2025.101700_bib0605","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.7150\/jca.26060","article-title":"Risk assessment and hydrodissection technique for radiofrequency ablation of thyroid benign nodules","volume":"9","author":"Xiaoyin","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ando.2025.101700_bib0610","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s40618-023-02078-4","article-title":"Effectiveness and safety of the radiofrequency ablation of single hyperfunctioning parathyroid lesions suggestive of adenomas in primary hyperparathyroidism","volume":"46","author":"Le\u00f3n Utrero","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101700_bib0615","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/02656736.2022.2047231","article-title":"Radiofrequency ablation for primary hyperparathyroidism and risk factors for postablative eucalcemic parathyroid hormone elevation","volume":"39","author":"Peng","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ando.2025.101700_bib0620","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3348\/kjr.2021.0716","article-title":"Efficacy and safety of ultrasound-guided radiofrequency ablation for primary hyperparathyroidism: a prospective study","volume":"23","author":"Chai","year":"2022","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ando.2025.101700_bib0625","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.eprac.2021.07.012","article-title":"Ultrasound-guided radiofrequency ablation for the treatment of primary hyperparathyroidism: an efficacy and safety study","volume":"27","author":"Li","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2025.101700_bib0630","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/02656736.2022.2029957","article-title":"Risk factors influencing cure of ultrasound-guided microwave ablation for primary hyperparathyroidism","volume":"39","author":"Liu","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ando.2025.101700_bib0635","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/02656736.2021.1945689","article-title":"Microwave ablation versus radiofrequency ablation for primary hyperparathyroidism: a multicenter retrospective study","volume":"38","author":"Wei","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ando.2025.101700_bib0640","first-page":"835","article-title":"Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism","volume":"36","author":"Liu","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ando.2025.101700_bib0645","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s00268-020-05885-5","article-title":"A review of parathyroid surgery for primary hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS)","volume":"45","author":"Ishii","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0650","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3348\/kjr.2020.0037","article-title":"Minimally invasive treatment for benign parathyroid lesions: treatment efficacy and safety based on nodule characteristics","volume":"21","author":"Ha","year":"2020","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ando.2025.101700_bib0655","doi-asserted-by":"crossref","first-page":"704","DOI":"10.21037\/gs-22-733","article-title":"Radiofrequency ablation of an intrathyroidal parathyroid adenoma with intraoperative parathyroid hormone monitoring: a case report of a novel technique","volume":"12","author":"Kandil","year":"2023","journal-title":"Gland Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0660","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0665","first-page":"9","article-title":"Treatment with hydrochlorothiazide and alendronate in patients with stones and bone mineral density loss. Evolution of bone metabolism and calciuria with medical treatment","volume":"69","author":"Arrabal-Mart\u00edn","year":"2016","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.ando.2025.101700_bib0670","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/jbmr.4694","article-title":"Denosumab for prevention of acute onset immobilization-induced alterations of bone turnover: a randomized controlled trial","volume":"37","author":"Wadiura","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0675","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0680","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0685","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa2209275","article-title":"Hydrochlorothiazide and prevention of kidney-stone recurrence","volume":"388","author":"Dhayat","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101700_bib0690","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ando.2025.101700_bib0695","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0700","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12020-014-0381-0","article-title":"Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication","volume":"49","author":"Marotta","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2025.101700_bib0705","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","article-title":"Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database","volume":"255","author":"Keutgen","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ando.2025.101700_bib0710","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0715","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1245\/s10434-011-2065-9","article-title":"Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use","volume":"19","author":"Norman","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2025.101700_bib0720","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0725","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1530\/EC-20-0221","article-title":"Cinacalcet and primary hyperparathyroidism: systematic review and meta regression","volume":"9","author":"Ng","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2025.101700_bib0730","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fendo.2017.00079","article-title":"Contemporary medical management of primary hyperparathyroidism: a systematic review","volume":"8","author":"Leere","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0735","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0740","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2025.101700_bib0745","article-title":"Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: a systematic review and meta-analysis","volume":"12","author":"Rajput","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0750","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/jbmr.4685","article-title":"The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Ye","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0755","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2025.101700_bib0760","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism","volume":"32","author":"Tournis","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0765","first-page":"480","article-title":"Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism","volume":"110","author":"Jansson","year":"1991","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0770","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2265.1990.tb00869.x","article-title":"Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status","volume":"32","author":"Schmidli","year":"1990","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0775","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00774-021-01279-2","article-title":"Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism","volume":"40","author":"Choe","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2025.101700_bib0780","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.surg.2019.04.059","article-title":"Skeletal effects of combined medical and surgical management of primary hyperparathyroidism","volume":"167","author":"Orr","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2025.101700_bib0785","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-21-0322","article-title":"Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study","volume":"185","author":"Ryh\u00e4nen","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0790","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40618-018-0829-9","article-title":"Denosumab or oral bisphosphonates in primary osteoporosis: a \u201creal-life\u201d study","volume":"41","author":"Cairoli","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101700_bib0795","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2025.101700_bib0800","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency","volume":"81","author":"Gronskaya","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2025.101700_bib0805","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.eprac.2022.09.006","article-title":"Withdrawal of denosumab in patients with primary hyperparathyroidism: a follow-up report of the DENOCINA study","volume":"28","author":"Leere","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2025.101700_bib0810","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2025.101700_bib0815","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ando.2025.101700_bib0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2025.101700_bib0825","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101700_bib0830","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4158\/EP10202.OR","article-title":"Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density","volume":"17","author":"Chandran","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2025.101700_bib0835","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101700_bib0840","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1530\/EC-21-0258","article-title":"A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism","volume":"10","author":"Bell","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2025.101700_bib0845","first-page":"750","article-title":"Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate","volume":"45","author":"Szymczak","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2025.101700_bib0850","first-page":"1076","article-title":"Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism","volume":"36","author":"Akbaba","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101700_bib0855","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/14782715231159741","article-title":"Utility of denosumab therapy in management of severe hypercalcaemia caused by primary hyperparathyroidism\u00a0\u2013\u00a0case report with review of literature","volume":"53","author":"Jadhao","year":"2023","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.ando.2025.101700_bib0860","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T20:10:50Z","timestamp":1740514250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0003426625000198"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101700","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chapter 11: Treatment modalities","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101700"}}